MedTrace Logo

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2013-07-22

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.

Conditions

Interventions

DRUG

Rosiglitazone

2mg to begin then 4mg, twice daily for 4 months

DRUG

Placebo

Subject receives placebo.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Sonia Caprio, MD · Yale School of Medicine Department of Pediatric Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-09-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413335 on ClinicalTrials.gov